ready-to-wear innovation

Innovative Houston athleisure startup debuts in Talbots

Houston-based Accel Lifestyle's innovative line of athleisure has made it into Talbots. Photo courtesy of Accel

After a year of planning and behind-the-scenes work, the highly anticipated collaboration between local apparel brand Accel Lifestyle and Talbots has finally come to fruition.

Shoppers can now find Accel Lifestyle apparel — beloved for its eco-friendly, sustainable, antibacterial fabrics sourced made in the USA — on Talbot's website.

This partnership marks the first-ever collaboration for the athleisure brand of Talbots, T by Talbots. By teaming up with Accel Lifestyle, Talbots expands its product offerings and also provides its loyal, forward-thinking, and ethically minded customers with a new clothing option that perfectly fits with their values.

At the helm of Accel Lifestyle is founder Megan Eddings, whose background in chemistry ignited the creation of the brand's groundbreaking Prema fabric after one too many run-ins with foul-smelling gym clothes. Her proprietary fabric boasts a revolutionary antibacterial technology, rendering Accel Lifestyle's apparel supremely comfortable, high-quality, and remarkably odor-resistant. With this cutting-edge fabric, Accel Lifestyle firmly establishes itself as a trailblazer in the industry, setting new standards for functionality and style.

As CultureMap reported in 2019, Eddings's innovative work was rewarded with a partnership with Inc. Magazine, Houston billionaire Tilman Fertitta, and others.

Amanda Cotler and Megan Eddings of Accel Lifestyle are celebrating a big win for their company. Photo courtesy

"We are beyond elated about the Accel x Talbots launch," Eddings tells CultureMap." Amanda Cotler, Accel's Director of Operations, and I have been working on this opportunity for a year, and it feels incredible for the collaboration to be live. Our passions are textiles with technology and an ethical made-in-the-USA supply chain. To have a multi-billion dollar company like Talbots care about the same things brings us so much joy."

In addition to their remarkable achievements in fashion, Accel Lifestyle champions the power of women in STEM through their team's leadership and this collaboration. By showcasing the applications of science and technology within the realm of fashion, Accel Lifestyle and Talbots are spotlighting the remarkable potential within these fields.

With the Accel Lifestyle x Talbots collaboration in full swing, customers can expect an extraordinary fusion of sustainable fashion and impeccable style. The Accel Lifestyle collaboration features an Anti-Odor Power Tank and an Anti-Odor Timeless Tee. Both are available in colors black and white.

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted